Learning Objectives:

1. Discuss current approved hematologic CAR-T cell therapies and considerations in terms of treatment sequencing pre- and post-CAR-T, management of side effects, and harnessing community resources to ensure appropriate community oncology referral and collaboration.

2. Explore the landscape of phase I trials of T cell therapy in solid tumors, including examples of appropriate patients to consider for referral and ways to co-manage with community providers.

3. Consider the roles of other immunologic therapies in the context of above T-cell therapies, such as oncolytic viral therapy in melanoma, or bispecific T cell engagers/antigen drug conjugates in hematologic malignancies.